The Biosulin equivalence in standard therapy (BEST) study − a multicentre, open-label, non-randomised, interventional, observational study in subjects using Biosulin 30/70 for the treatment of insulin-dependent type 1 and type 2 diabetes mellitus

David Grant Segal, Daniela Tupy, Larry A Distiller
2013 South African Medical Journal  
doi:10.7196/samj.6345 pmid:23802207 fatcat:i4j3fqjzijfmfe6iwlkhosp3wu